We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Modeling Impaired Judgement in Cocaine Abusers - 6

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00015236
Recruitment Status : Completed
First Posted : April 18, 2001
Last Update Posted : January 12, 2017
New York MDRU
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is for the modeling of impaired judgement in cocaine abusers.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorders Substance-Related Disorders Behavioral: Amantadine Phase 4

Detailed Description:
The objective of this study is to investigate recognition memory and appreciation of changing contingencies in relation to a response judgement.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 0 participants
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Modeling Impaired Judgement in Cocaine Abusers
Study Start Date : March 1997

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

(3 groups)Normal, healthy controls. Recent cocaine experience. Over 6 months since the last cocaine experience.

Exclusion Criteria:

Psychosis or mood disorder. History of seizure, head trauma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00015236

United States, New York
New York MDRU
New York, New York, United States, 10010
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
New York MDRU
Principal Investigator: John Rotrosen, M.D. New York MDRU

NIDA Research Monograph Series 179, 1998 CPDD 98, 99.

ClinicalTrials.gov Identifier: NCT00015236     History of Changes
Other Study ID Numbers: NIDA-5-0013-6
First Posted: April 18, 2001    Key Record Dates
Last Update Posted: January 12, 2017
Last Verified: June 1998

Additional relevant MeSH terms:
Substance-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Antiviral Agents
Anti-Infective Agents
Analgesics, Non-Narcotic